Both safety and efficacy of medical treatment can vary depending on the ethnogeographic
background of the patient. One of the reasons underlying this variability is differences in …

The CYP2D6 gene has been widely studied to characterize variants and/or star alleles,
which account for a significant portion of variability in drug responses observed within and …

Racial and ethnic differences in drug responses are now well studied and documented.
Pharmacogenomics research seeks to unravel the genetic underpinnings of inter-individual …

Underrepresentation of subpopulations within geo-ancestral groups engaged in research
can exacerbate health disparities and impair progress toward personalized medicine. This is …

The association of an individual's genetic makeup with their response to drugs is referred to
as pharmacogenomics. By understanding the relationship between genetic variants and …

Background Adverse drug reactions are a major concern in drug development and clinical
therapy. Genetic polymorphisms in genes involved in drug metabolism and transport are …

Genetic factors have long been recognized as important determinants of interindividual
variability in drug efficacy and toxicity. However, despite the increasing number of …

Health disparities exist among minorities in the United States, with differences seen in
disease prevalence, mortality, and responses to medications. These differences are …

Abstract CYP2C19 and CYP2D6 are important drug-metabolizing enzymes that are involved
in the metabolism of around 30% of all medications. Importantly, the corresponding genes …

Genetic variation in CYP2B6 and CYP2A6 is known to impact interindividual response to
antiretrovirals, nicotine, and bupropion, among other drugs. However, the full catalogue of …